Title:

Impact of Standard versus Extended Natalizumab Dosing and Treatment Withdrawal on Relapse, Disability, MRI Activity and Safety in Adults with MS: A Systematic Review and Meta-Analysis

Authors:

- Vihaan Sahu
  ORCID: 0009-0008-5790-1818
  Georgian National University SEU, Tbilisi, Georgia
  No conflict of interest declared.

- Mohith Balakrishnan
  ORCID: 0009-0000-6053-7043
  Georgian National University SEU, Tbilisi, Georgia
  No conflict of interest declared.

- Dhaneesh Rucher Jetty
  ORCID: 0009-0005-7414-495X
  Georgian National University SEU, Tbilisi, Georgia
  No conflict of interest declared.

Corresponding Author:
Vihaan Sahu
Email: vsahu@seu.edu.ge

Author Note:
This manuscript is currently under consideration at Multiple Sclerosis and Related Disorders (Elsevier).

Acknowledgments:
Not applicable.

Abstract

Background: Natalizumab is a high-efficacy therapy for relapsing-remitting multiple sclerosis (RRMS). Balancing efficacy with the risk of progressive multifocal leukoencephalopathy (PML) is critical. Uncertainty persists regarding the comparative effectiveness of standard interval dosing (SID; every 4 weeks) versus extended interval dosing (EID; every 5-8 weeks) and the outcomes following treatment cessation.

Objectives: To systematically compare the efficacy and safety of natalizumab SID versus EID, and to quantify the absolute risk of relapse and disability progression after treatment cessation in adults with RRMS.

Methods: We conducted a systematic review and meta-analysis (PROSPERO: CRD420251103014) following PRISMA guidelines. We searched MEDLINE, Cochrane Library, ClinicalTrials.gov, and other sources (2015-2025) for randomized controlled trials and observational studies. Primary outcomes were annualized relapse rate (ARR) and disability progression; secondary outcomes included PML incidence and post-cessation relapse. Risk of bias was assessed using Cochrane RoB 2.0 and ROBINS-I. Data were synthesized narratively or via meta-analysis where appropriate, with evidence certainty graded (GRADE).

Results: Twenty-eight studies (3 RCTs, 24 observational studies, 1 case series; n=45,803 participants) were included. Narrative synthesis of ARR (9 studies) showed no consistent difference between SID and EID, with ARR values being very low in both groups. Meta-analysis of PML risk from three studies with events found no significant difference (RR 0.70, 95% CI 0.20–2.54). Disability outcomes were infrequently and heterogeneously reported, precluding meta-analysis. After cessation, the pooled proportion of patients relapsing within 12 months across 4 studies (n=857) was 37.6% (95% CI 34.4–40.9%). The certainty of evidence was low for most outcomes.

Conclusions: EID appears to maintain relapse control comparable to SID. The evidence regarding a reduced PML risk with EID is inconclusive due to imprecision and residual confounding. Cessation carries a high absolute risk of disease reactivation, demanding an immediate transfer to alternate therapy. These data indicate EID as a viable choice for stable individuals, although decisions must be made individually. To definitively estimate PML risk, future research will require uniform outcome definitions as well as bigger, prospective trials.

Keywords: Natalizumab, multiple sclerosis, relapsing-remitting, extended interval dosage, treatment discontinuation, meta-analysis, progressive multifocal leukoencephalopathy.

1. Introduction

1.1 Background and Significance

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system that causes neurological impairment and progressive disability accumulation, limiting overall function and quality of life. Globally, the condition affects around 2.8 million people (1). The relapse-remitting form of MS (RRMS) accounts for 85-90% of initial presentations, has a 3:1 female predominance, and usually manifests in patients' third to fourth decades (2, 3). Hospitalization and large medical expenses are common among patients with severe RRMS, emphasizing the crucial need for effective disease-modifying therapy (4, 5).

Natalizumab, a humanized monoclonal antibody targeting α4-integrin, inhibits lymphocytes from crossing the blood-brain barrier, reducing CNS inflammation and relapse activity (6, 7). Since its FDA approval in 2004, natalizumab has demonstrated significant decreases in relapse frequency and MRI lesion burden in important trials (8, 3, 2). Following reports of progressive multifocal leukoencephalopathy (PML) in 2005, risk management strategies such as patient screening and JC virus surveillance were implemented (9, 10). Despite these developments, questions about optimal dosing regimens and safe withdrawal continue to arise. While standard four-week dose maintains α4-integrin receptor saturation above 80%, extended interval dosing (EID, 5-8 weeks) may reduce PML risk while maintaining efficacy (5). Discontinuation carries a 3-6-month risk of illness reactivation, emphasising the importance of evidence-based bridging treatments.

1.2 Current Evidence and Gaps

The phase 2 and pivotal studies consistently shown lower recurrence rates and MRI lesion activity (8, 3, 2, 11). Early meta-analyses confirmed efficacy, but were restricted by short follow-up periods, dose variability, and a lack of long-term safety and post-cessation evidence. Nikfar et al. (12) (2010) analyzed four studies (n = 1,407) and discovered a 50% reduction in relapse risk, but the implications for real-world practice remained questionable. Observational studies, such as Salhofer-Polanyi et al. (13) (2014), indicate the danger of rebound following cessation, but variability in design and outcomes prevents definitive guidance. Recent systematic reviews, including Rabea et al. (14) (2024), explored safety and efficacy up to June 2023 but did not cover post-cessation outcomes or research beyond 2025, stressing the need for a modern synthesis that incorporates trial and observational data.

1.3 Rationale for this Review

While the efficacy of natalizumab has been demonstrated, information on EID and post-discontinuation outcomes remains fragmented. Real-world accounts emphasize rebound risk and the significance of bridging techniques, but heterogeneity limits conclusive guidance. This review builds on previous work by including studies from 2023-2025, combining trial and real-world data, and focusing on dose optimization and cessation to inform interval management techniques.

1.4 Objectives

This systematic review and meta-analysis aims to evaluate Natalizumab in adults with RRMS, with an emphasis on dosing strategies and outcomes after cessation. Using a PICO framework, the objectives are:

- To compare the efficacy of standard-interval dosing (SID) versus extended-interval dosing (EID) on annualized relapse rate (ARR), disability progression, and MRI outcomes.
- To quantify the absolute risk, timing, and severity of relapse and disability progression following treatment cessation.
- To evaluate safety profiles, particularly the incidence of PML.
- To synthesize real-world and trial evidence from 2015 onward.
- To support clinical decision-making by offering evidence on dose optimization and cessation procedures.

2. Methods

2.1 Protocol and Registration

This systematic review was conducted according to a predefined protocol registered on PROSPERO (CRD420251103014). The protocol specified the search strategy, eligibility criteria, outcomes, risk-of-bias assessment methods, and synthesis approach. The review is reported in accordance with the PRISMA 2020 statement (15).

2.2 Eligibility Criteria

Studies were selected based on the PICO framework:

- Population: Adults (≥18 years) with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab monotherapy.
- Intervention: 1) Standard-interval dosing (SID) of natalizumab (every 4 weeks), or 2) Cessation of natalizumab therapy.
- Comparator: 1) Extended-interval dosing (EID; infusion intervals typically >4 weeks, up to 8 weeks), or 2) For cessation studies, either continuation of natalizumab or no active comparator (natural history).
- Outcomes:The primary outcomes were the annualized recurrence rate (ARR) and disability progression (confirmed EDSS deterioration). Secondary outcomes included No Evidence of Disease Activity (NEDA-3), recurrence risk after cessation, MRI activity, and safety outcomes, specifically the incidence of progressive multifocal leukoencephalopathy (PML).

- Study Designs: Randomized controlled trials (RCTs), prospective and retrospective cohort studies, and case series (for cessation results) were all included. Studies were omitted if they were reviews, conference abstracts without full data, addressed pediatric populations, coupled natalizumab with other disease-modifying treatments, or did not provide relevant outcomes. To reflect current practice, the publishing date range began on January 1, 2015. While the protocol specified studies from 2015 onward, one study (16)) was first published online in November 2014 but assigned to a 2015 journal issue; given its direct relevance, it was retained. This represents a minor deviation from the protocol. Only English-language publications were included.

2.3 Information Sources

Comprehensive searches were performed in MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), Google Scholar, Sage Journals, Frontiers, eLife, BMJ Neurology Open, and ClinicalTrials.gov. Reference lists of included articles and relevant systematic reviews were manually screened for additional studies. Corresponding authors were contacted for missing data where necessary.

2.4 Search Strategy

Search strategies utilized a combination of controlled vocabulary (e.g., MeSH terms) and keywords related to "natalizumab," "multiple sclerosis," "extended interval dosing," "standard interval dosing," "cessation," "relapse," "disability progression," and "PML." Search filters limited results to human studies and English language, with a publication date from January 1, 2015. The search strategy was tailored for each database and is available on PROSPERO protocol registration.

2.5 Study Selection

Search results were imported into Zotero 6.0.30 for duplicate removal. Title/abstract screening and subsequent full-text assessment were performed independently by two reviewers (V.S., M.B.) using Rayyan QCRI (17) . Conflicts were resolved through discussion or by a third reviewer (D.J.). The study selection process is detailed in the PRISMA flow diagram (18) (Figure 1).

Figure 1: PRISMA flow chart

2.6 Data Collection Process

Data extraction was conducted independently by two reviewers (V.S., D.J.) using a standardized, piloted data extraction form in LibreOffice and Word. Disagreements were resolved by consensus or third-party adjudication (M.B.). Study authors were contacted for clarification or additional data when reported information was incomplete.

2.7 Data Items

Extracted data included:

- Study characteristics (design, country, funding, conflicts of interest).
- Participant characteristics (sample size, demographics, baseline disease characteristics).
- Intervention and comparator definitions (specific EID interval, cessation reason, post-cessation management).
- Outcome data for all pre-specified efficacy and safety endpoints, including effect estimates, measures of dispersion, and raw counts/denominators where available.

2.8 Risk of Bias in Individual Studies

The risk of bias was assessed independently by two reviewers (V.S., M.B.).

- RCTs (n = 3) were evaluated using the Cochrane RoB 2.0 tool (19).
- Non-randomized studies (n = 24) were assessed using the ROBINS-I tool (20).
- Case series (n = 1) were appraised using the Joanna Briggs Institute (JBI) critical appraisal checklist (21).

Results are summarized graphically in Supplementary Figure 1A (RCTs) and Supplementary Figure 1B (non-randomized studies), which were generated using the robvis visualization tool (22). Detailed domain-level judgments for all studies are provided in Supplementary Table 1.

2.9 Synthesis Methods

The approach to synthesis was determined by the degree of clinical and methodological homogeneity among studies for each outcome.

- Meta-analysis was performed when at least two studies reported an outcome with consistent definitions and provided data suitable for pooling (e.g., raw event counts for dichotomous outcomes, means and standard deviations for continuous outcomes). Random-effects models were used due to anticipated heterogeneity. Heterogeneity was quantified using the I^2 statistic. For rare events like PML, the meta-analysis of the risk ratio (RR) included only studies that reported events. Studies with zero events in both arms were tabulated separately for context. Studies reporting person-years (PY) were analyzed separately (Incidence Rate Ratio) to avoid statistical flaws.

- Narrative Synthesis was employed for outcomes where meta-analysis was precluded due to extreme heterogeneity in outcome definitions (e.g., at least five different definitions of "EDSS worsening"), intervention parameters (EID intervals ranging from ~5 to 8 weeks), or incomplete data reporting. This synthesis followed the Synthesis Without Meta-analysis (SWiM) guidelines (23), presenting a structured descriptive summary of results, including the direction of effect and range of estimates.

Sensitivity analyses (e.g., leave-one-out) were conducted to assess the robustness of meta-analytic findings. The certainty of the evidence for each outcome was evaluated using the GRADE framework (24), as summarized in Supplementary Table 4.

2.10 Software

Zotero 6.0.30 (deduplication), Rayyan QCRI (screening) (17) , R statistical software (25) (meta-analysis) with the meta package (26), and LibreOffice / Word (data extraction and management) were used.

3. Results

3.1 Study Selection

Our systematic search identified 1,338 records (1,316 from databases and 22 from trial registries), with an additional 12 records found through citation searching. After removing 297 duplicates, 1,041 titles and abstracts were screened, of which 818 were excluded for irrelevance.

We assessed 223 full texts from databases/registries and 12 from citation searches. Nine full texts (7 database/register, 2 citation) could not be retrieved. Of the remaining 225 reports, 199 (189 database/register and 10 citation) were excluded due to ineligible study design, population, intervention, or outcomes.

Ultimately, 28 studies met inclusion criteria (27 from databases/registries, 1 from citation searching). The PRISMA 2020 flow diagram (18) (Figure 1) summarizes the selection process, and excluded studies are listed in Supplementary Table 2.

3.2 Study Characteristics

The 28 included studies (2015–2025) comprised 3 randomized controlled trials (RCTs), 24 observational studies (prospective and retrospective cohorts), and 1 case series. Across all studies, the total sample size was 45,803 participants, although one large registry (Ryerson et al. (27), n=35,521) heavily influenced this number. Studies were conducted in single-country or multinational settings across Europe, North America, the Middle East, and Australia.

Two primary comparisons were addressed:

- Standard-Interval Dosing (SID) vs Extended-Interval Dosing (EID) of natalizumab, with EID definitions ranging from >5 weeks to 8-week intervals.
- Outcomes after cessation of natalizumab.

The key reported outcomes were annualized recurrence rate (ARR), disability progression (EDSS worsening), NEDA-3, PML incidence, and post-cessation outcomes (relapse rates, time to relapse, and EDSS worsening). Funding was disclosed for 22 trials, with 10 getting industrial support, largely from Biogen. Table 1 summarizes the detailed study characteristics, including the baseline demographics.

TABLE 1. Characteristics of Included Studies

Study (Author, Year)	Country	Study Design	Sample Size (Total N)	Comparison Groups	Funding Source / Conflict of Interest	Notes
Al-Mahdawi et al., 2023 (28)	Iraq	Observational Retrospective Cohort	150	SID (Q4W), EID (definition NR)	NR	Multicenter, aggregated data only (contributed to narrative context)

Bernardes et al., 2024 (29)	Portugal	Retrospective observational cohort	76	SID (Q4W) vs EID (Q6W)	No specific grant; COI disclosed	Single-center, within-patient comparison
Butzkueven et al., 2020 (TOP) (30)	Multinational	Prospective Observational Registry	472 (matched)	SID (Q4W), EID (Q6W)	Supported by Biogen; multiple author COIs	Multicenter registry, propensity score-matched
Clerico et al., 2019 (31)	Italy	Retrospective Cohort	360	SID (<5 weeks), EID (≥5 weeks)	NR	Multicenter (14 centers)
Coerver et al., 2021 (32)	Netherlands	Retrospective Observational Cohort	147	Cessation	ZonMW grant, Stichting MS Research grant	Monocentric, outcomes after cessation
De Mercanti et al., 2021 (33)	Italy	Retrospective cohort	316	SID (<5w) vs EID (≥5w)	Not reported	Multicenter (14 centers)
Foley et al., 2022 (NOVA) (34)	Multinational (11 countries)	RCT (open-label, rater-blinded)	499	SID (Q4W) vs EID (Q6W)	Biogen	Multicenter (89 centers), phase 3b trial
Fuentes-Rumí et al., 2020 (35)	Spain	Retrospective observational	50	Cessation	No specific grant; COI disclosed	Single-center, IVMP washout strategies
Gardinetti et al., 2017 (36)	Italy	Retrospective Cohort	30	Cessation	All authors have nothing to declare	Multicenter (2 centers), outcomes after cessation
González-Suarez et al.,	Spain	Case series	4	Cessation → switch to	"No conflict of	Multicenter (3 hospitals),

2017 (37)				FTY	interest"	rebound cases
Haas et al., 2016 (38)	Germany	Prospective cohort	57	SID (Q4W) vs Cessation (Wash-out)	German Ministry for Education and Research; "none declared"	Single-center, immunology focus
Jakimovski et al., 2023 (39)	USA (NY)	Retrospective cohort	242	Continue SID (Q4W) vs Discontinue (Cessation)	Biogen; Multiple authors disclosed industry funding	Consortium data, includes SPMS/PPMS patients
Jeantin et al., 2023 (40)	France	Retrospective Self-Controlled Cohort	57	SID (Q4W), EID (Q6W)	No funding; some author COIs	Monocentric, within-patient comparison
Kaufman et al., 2015 (RESTORE) (41)	Multinational	RCT	175	Continue Natalizumab (Q4W), Placebo (Cessation)	Funded by Biogen Idec Inc.	Multicenter, partially placebo-controlled
Kister et al., 2018 (42)	Multinational (20 centers)	Retrospective registry cohort	4842	Cessation (vs other DMTs)	MSBase Foundation; "No targeted funding"	MSBase registry, natalizumab cessation arm n=308
Mustonen et al., 2020 (43)	Finland	Retrospective cohort	89 (85 RRMS)	Cessation	Hospital grants; personal grants; honoraria/consultancies	Multicenter (4 hospitals), RRMS n=85 for PICO
Papeix et al., 2016 (44)	France	Prospective observational registry	715	Cessation	No targeted funding; COI disclosed	Nationwide multicenter (TYSEDMUS

						registry)
Pelle et al., 2023 (45)	France	Retrospective cohort	303	SID (Q4W) vs EID (5-6w)	Caen University Hospital; additional funding from Biogen	Multicenter (5 centers)
Riancho et al., 2021 (46)	Spain	Retrospective Cohort	39	SID (Q4W), EID (Q8W)	Supported by IDIVAL; various author COIs	Monocentric, within-patient comparison (sequential arms)
Ruggieri et al., 2019 (47)	Italy	Retrospective Cohort	775	SID (≤35 days), EID (>35 and ≤56 days)	NR	Multicenter, includes a mixed-dose arm
Ryerson et al., 2015 (48)	USA	Registry Analysis	1998	SID (Q4W ±2d), EID (4w3d-8w5d)	No grant or industry support	Multicenter registry
Ryerson et al., 2019 (27)	USA	Retrospective Cohort (TOUCH)	35,521	SID (various def.), EID (various def.)	Funded by Biogen	TOUCH registry, analysis of PML risk only
Toljan et al., 2024 (49)	Italy	Retrospective Cohort	745	SID (Q4W), EID (>5-7 weeks), EID (>7-8 weeks)	Multiple author COIs with pharma companies	Multicenter (8 centers), arm Ns not reported

Toorop et al., 2024 (50)	Netherlands	Retrospective Cohort	82	SID (Q4W), EID (≥5 weeks)	Dutch MS Research Foundation, Brain Foundation Netherlands, Innovation Fund Healthcare insurers	Monocentric
van Kempen et al., 2020 (51)	Netherlands	Prospective single-arm trial	61	EID (Personalized)	Brain Foundation Netherlands; Various COI disclosures	Multicenter, no SID comparator arm
Vidal-Jordana et al., 2015 (16)	Spain	Prospective observational cohort	47	Cessation	No specific grant	Single-center, outcomes after cessation
Weinstock-Guttman et al., 2016 (52)	USA	RCT (single-blinded MRI)	50	Cessation: Tapered (EID-like) vs Immediate	Biogen Idec (Investigator-initiated)	Single-center, phase IV, includes relapsing-SPMS
Yamout et al., 2018 (53)	Lebanon, Iran	Retrospective Review of Registry Cohorts	85	SID (Q4W), EID (≥5 weeks)	None	Multicenter (2 centers), within-patient comparison

Footnote: SID = standard-interval dosing; EID = extended-interval dosing; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; PPMS = primary progressive multiple sclerosis; NR = not reported.

3.3 Risk of Bias

RCTs (n=3) were evaluated using ROB 2 (19): two were judged low risk, while one raised some concerns due to deviations from intended interventions.
Non-randomized studies (n=24) were assessed with ROBINS-I (20): 20 had moderate risk and 4 serious risk.

Confounding and missing data were the most common sources of bias. A case series (37) assessed with the JBI checklist was deemed moderate risk. Full risk-of-bias judgments are provided in Supplementary Table 1 and Supplementary Figures 1A and 1B.

3.4 Synthesis of Results

Feasibility of quantitative meta-analysis was pre-assessed for each outcome based on clinical and methodological homogeneity (Supplementary Table 3).

3.4.1 SID vs EID: Efficacy Outcomes (ARR)

Thirteen studies reported ARR, of which 9 provided data suitable for descriptive synthesis. ARR values were consistently low across both dosing strategies (range: 0.0006–0.14).

Based on the direction of point estimates, four studies reported a lower ARR with EID, three reported a lower ARR with SID, and two reported identical or nearly identical ARR between groups.

- The median ARR difference (EID – SID) was 0.000 (range –0.050 to +0.014).
- Pelle 2023 (45) was the only study allowing formal IRR estimation (IRR 0.44; 95% CI 0.16–1.26), showing no significant difference.

Table 3A summarizes ARR outcomes. Meta-analysis was not possible due to heterogeneity in EID definitions, outcome reporting, and lack of raw event data.

Summary: Both SID and EID maintained very low relapse activity. No strategy consistently outperformed the other.

Table 3A: ARR Comparison: Study Characteristics and Reported Outcomes

Study	EID Definition	Reported ARR (Quote/Direct Summary)	Notes
Bernardes 2024 (29)	6 weeks	ARR, median (IQR) 0 (0) [SID] vs 0 (0) [EID]; Relapses: 1 [SID] vs 4 [EID], p=0.083	Within-patient comparison; PY not reported
Clerico 2019 (31)	≥5 weeks	Adjusted ARR: 0.060 (95% CI 0.033–0.087) [SID] vs 0.039 (95% CI 0.017–0.063) [EID]	Adjusted mean; no raw counts/PY
De Mercanti 2021 (33)	≥5 weeks	ARR 0.075 (SD 0.20) [SID] vs 0.089 (SD 0.22) [EID]	Pre-intervention period

Foley 2022 (34)	6 weeks	Unadjusted ARR 0.0171 [SID] vs 0.0228 [EID]; Adjusted ARR: 0.00010 (95% CI 0.00004–0.00024) [SID] vs 0.00013 (95% CI 0.00006–0.00027) [EID]	Relapse counts not reported
Jeantin 2023 (40)	6 weeks (42 ± 7 days)	ARR 0.0 [SID] vs 0.0 [EID]	Zero relapses; PY calculable
Pelle 2023 (45)	5–6 weeks (≤9 infusions/12mo)	ARR 0.083 (SD 0.300) [SID] vs 0.041 (SD 0.231) [EID]; Relapses: 12/156 [SID] vs 5/147 [EID]	Only study with counts & PY suitable for IRR
Riancho 2021 (46)	8 weeks	ARR 0.025 (SD 0.026) [SID] vs 0.020 (SD 0.060) [EID]; p=0.72	Mean ARR only
Ryerson 2015 (48)	4.5–8.5 weeks	ARR 0.14 [SID] vs 0.09 [EID]	Mean ARR only
Yamout 2018 (53)	≥5 weeks	ARR 0.0006 ± 0.003 [SID] vs 0.001 ± 0.006 [EID]; p=0.42	Mean ARR and SD

Footnotes: SID = standard-interval dosing; EID = extended-interval dosing; ARR = annualized relapse rate; SD = standard deviation; PY = person-years; CI = confidence interval.

Figure 2. Annualized Relapse Rate (ARR) Values by Study (Narrative Synthesis).

Figure 3. Annualized Relapse Rate (ARR) Comparison: SID vs EID across the included studies.

3.4.2 SID vs EID: Disability Progression and NEDA-3

Heterogeneous outcome definitions and insufficient reporting prevented quantitative synthesis.

- Foley 2022 (34): 24 weeks of reported disability worsening: 92% [SID] vs 90% [EID] progression-free;
- NEDA-3: 163/242 [SID] vs 173/247 [EID].
- Pelle 2023 (45): Unconfirmed EDSS worsening: 13% [SID] versus 11% [EID].
- Riancho 2021 (46): Partial NEDA-3 reporting for EID only.

Table 3B presents study-specific outcomes.

Summary: Disability progression and NEDA-3 failure rates were modest across all regimens. The evidence shows equivalency, although comparability was constrained by inconsistent outcome criteria.

Table 3B: Disability Progression and NEDA-3 Outcomes

Outcome	PICO Comparison	Study	Outcome Definition	Reported Results	Notes
EDSS Worsening	SID vs EID	Foley 2022 (34)	24-week confirmed disability worsening	% free of progression: 92% [SID] vs 90% [EID]	Raw event counts not reported.
	SID vs EID	Pelle 2023 (45)	Worsening of EDSS score (not confirmed)	20 (13%) [SID] vs 14 (11%) [EID]	Definition is not confirmed disability progression.
	After Cessation	Vidal-Jordana 2015 (16)	Increase of ≥1.5 or ≥1.0 point at 6-12mo	Eight patients (19%) presented significant clinical worsening	Single arm reporting only.
NEDA-3	SID vs EID	Foley 2022 (34)	No relapses, no new MRI lesions, no 24-wk	NEDA-3: 163/242 [SID] vs 173/247 [EID]	Only study reporting complete NEDA-3 data.

	SID vs EID	Riancho et al., 2021 (46)	Not fully defined	Proportions for EID arm only (94%, 73%, 70%)	Incomplete reporting; no SID data.

Footnote: EDSS = Expanded Disability Status Scale; CDW = Confirmed Disability Worsening; NEDA-3 = No Evidence of Disease Activity (relapses, MRI activity, and CDW)

3.4.3 SID vs EID: Safety Outcome (PML)

Nine studies reported on PML. The meta-analysis of the risk ratio (RR) included the three studies that reported PML events. Five additional studies reported zero events in both arms and are presented in Table 3C for context; these were not included in the pooled RR calculation as they provide no information on the relative effect.

- Primary pooled analysis (3 studies with events): RR 0.70 (95% CI 0.20–2.54), I^2=0%.
- Sensitivity analysis (excluding Foley 2022 (34) asymptomatic case): RR 0.54 (95% CI 0.13–2.17).
- Person-year analysis ((48)): IRR 0.11 (95% CI 0.01–1.99).

Table 3C summarizes study-level PML data.

Summary: No significant difference in PML risk was detected between SID and EID, though precision was limited by rare events. Ongoing monitoring is warranted.

Table 3C: PML Incidence in Patients on Standard-Interval Dosing (SID) vs. Extended-Interval Dosing (EID)

Study (First Author, Year)	Dosing Group	Population at Risk	PML Events (n)	Key Notes
Studies Included in RR Meta-analysis				
Butzkueven et al., 2020 (30)	SID	210 (N)	2	Safety population
	EID	236 (N)	2	Safety population
Ryerson et al., 2019 (27)	SID	4801 (N)*	19	Adjusted JCV-positive

				patients
	EID	810 (N)	1	Adjusted JCV-positive patients
Foley et al., 2022 (34)	SID	242 (N)	0	Clinical & MRI monitoring
	EID	247 (N)	1	Asymptomatic case via MRI

Study with Person-Year Data (Analyzed Separately)

Ryerson et al., 2015 (48)	SID	1052 PY**	4	**JCV-positive person-years
	EID	1090 PY**	0	**JCV-positive person-years

Studies with Zero PML Events (Descriptive Context)

Clerico et al., 2019 (31)	SID	216 (N)	0	Follow-up up to 2 years
	EID	144 (N)	0	Follow-up up to 2 years
Pelle et al., 2023 (45)	SID	156 (N)	0	12 months follow-up
	EID	147 (N)	0	12 months follow-up
Riancho et al., 2021 (46)	SID	39 (N)	0	Mean follow-up: 51.1 months

	EID	39 (N)	0	Mean follow-up: 76.7 months
Toorop et al., 2024 (50)	SID	50 (N)	0	Follow-up not specified
	EID	32 (N)	0	Follow-up not specified
Yamout et al., 2018 (53)	SID	85 (N)	0	Follow-up not specified
	EID	85 (N)	0	Follow-up not specified

Footnote: EID: Extended-Interval Dosing; JCV: JC virus; MRI: Magnetic Resonance Imaging; N: Number of patients; PML: Progressive Multifocal Leukoencephalopathy; PY: Person-Years; SID: Standard-Interval Dosing

Figure 4: Forest Plot of PML Risk: SID vs EID (Main Analysis).

Supplementary Figure 2: Forest Plot of PML Risk is also provided which includes Sensitivity Analysis Excluding Foley et al. 2022 (34).

3.4.4 Outcomes After Cessation: Relapse and Disability

Four studies (n=857) reported the proportion of patients relapsing within 12 months post-cessation. This was meta-analyzed as a pooled proportion (absolute risk).

- Pooled proportion of patients relapsing: 37.6% (95% CI 34.4–40.9%).

- Heterogeneity: I²=66.1%, largely due to Weinstock-Guttman 2016 (52) (59.3%). Excluding this outlier reduced I² to 0%, with minimal change in pooled estimate (35.2%).

EDSS worsening rates post-cessation were highly variable (19–100%). Excluding the outlier study (González-Suarez et al., 2017 (37), n=4), the weighted mean was 23.1%. Median time to first relapse ranged from 3-9.8 months, clustering within the first 6 months.

Table 3D summarizes cessation outcomes.

Summary: Natalizumab cessation was associated with a high absolute risk of relapse (≥1/3 relapsing within 12 months) and frequent EDSS worsening, with most relapses occurring early.

Table 3D: Outcomes After Natalizumab Cessation

Study	N (Stop)	Primary Reason for Cessation	Follow-up post-cessation	% Relapse (12mo)	Median Time to First Relapse (months)	% with EDSS Worsening	Post-Cessation Strategy
Coerver et al., 2021 (32)	147	JCV positivity/PML risk (64.6%)	2 years	NR	6.1–9.8 (by group)	18.0–22.7%	No DMT, First-line, or Second-line DMT
Gardinetti et al., 2017 (36)	30	Planned interruption	Mean 18.8 mo	50%	6.0 (mean)	NR	Various (not specified)
Mustonen et al., 2020 (43)	85	Various	≥12 months	30.3%	3.0 (rebound subgroup)	NR	Switch to another DMT
Papeix et al., 2016 (44)	715	Various	Median 1.1 yr	37.1%	4.9	23%	Restart NTZ or switch to another DMT
Weinstock-Guttman et al., 2016 (52)	27	Study protocol	12 months	59.3%	NR	NR	Switch to another DMT

| González-Suarez et al., 2017 (37) | 4 | PML risk | NR | NR | 3.5 (mean) | 100% | Switch to fingolimod |
| Vidal-Jordana et al., 2015 (16) | 47 | PML risk, other | Mean 23.9 mo | NR | NR | 19% | Switch to another DMT |

Footnote: NR = Not Reported; DMT = disease-modifying therapy; NTZ = natalizumab.

Figure 5. Forest plot of the proportion of patients relapsing within 12 months after natalizumab cessation (random-effects model).

Study	Events	Total	Proportion	95%–CI	Pooled Relapse Rate	Proportion	95%–CI
Mustonen 2020	26	85	0.31	[0.21; 0.42]		0.31	[0.21; 0.42]
Papeix 2016	265	715	0.37	[0.34; 0.41]		0.37	[0.34; 0.41]
Gardinetti et al., 2021	15	30	0.50	[0.31; 0.69]		0.50	[0.31; 0.69]
Weinstock–Guttman 2016	16	27	0.59	[0.39; 0.78]		0.59	[0.39; 0.78]
Common effect model		857	**0.38**	**[0.34; 0.41]**		**0.38**	**[0.34; 0.41]**
Random effects model			**0.38**	**[0.34; 0.41]**		**0.38**	**[0.34; 0.41]**

Heterogeneity: $I^2 = 66.1\%$, $\tau^2 = 0.021$, $p = 0.0315$

0.3 0.4 0.5 0.6 0.7
Proportion of Patients with Relapse

Figure 6. Timeline of median/mean time to first relapse across studies reporting this outcome.

Figure 7. Bar plot of EDSS worsening rates after cessation. The weighted mean excluding the outlier (37) was 23.1%.

3.5 Sensitivity Analyses

Leave-one-out analyses confirmed robustness of pooled results for both PML risk and cessation relapse rates. Exclusion of single studies influenced heterogeneity but not overall interpretation (Supplementary Table 5).

3.6 Reporting Bias

Publication bias could not be formally assessed as each outcome had fewer than 10 studies, insufficient for funnel plots or statistical testing.

3.7 Certainty of Evidence (GRADE)

Certainty of evidence for each outcome is summarized in Supplementary Table 4:

- SID vs EID:
  o ARR = Low (risk of bias, inconsistency)
  o Disability progression = Very Low (bias, inconsistency, indirectness)
  o PML = Low (bias, imprecision)
  o NEDA-3 = Low (bias, imprecision, single study)

- Outcomes After Cessation:
  o Relapse = Low (bias, heterogeneity)
  o EDSS worsening = Very Low (bias, inconsistency, imprecision)

4. Discussion.

4.1. Interpreting the Results

This systematic review presents a complete synthesis of evidence comparing standard-interval dosing (SID) with extended-interval dosing (EID) of natalizumab in RRMS, including outcomes after treatment discontinuation. Our analysis includes 28 trials totaling 45,803 participants. The evidence showed significant clinical and methodological variation, which influenced our analytical approach.

The efficacy outcomes for SID vs. EID were similar in direction but varied in reporting. Across nine trials reporting ARR, the median difference (EID - SID) was zero. The point estimates fluctuated, with no clear trend favoring one technique over another. These findings indicate that EID provides relapse control comparable to SID. Similarly, when disability progression and NEDA-3 results were reported, they were modest and similar between groups, despite the limitations of different classifications.

The safety outcomes, specifically PML incidence, were meta-analyzed across the three studies that recorded occurrences. The pooled risk ratio was 0.70 (95% confidence interval: 0.20–2.54). While our point estimate

shows that EID may reduce PML risk, the confidence intervals are broad and can account for both clinically significant benefit and harm. The frequency of PML episodes, combined with the observational nature of the evidence, limits the certainty of this discovery.

The outcomes upon cessation were evident. The pooled proportion of patients relapsing within 12 months was 37.6%, indicating a substantial absolute risk of illness reactivation following natalizumab withdrawal and emphasizing the importance of proactive transition programs.

4.2. Limitations of the Evidence

The body of evidence has several important limitations. First, the predominance of observational studies introduces a high risk of confounding by indication. Second, extreme clinical and methodological heterogeneity precluded meta-analysis for several key outcomes. Third, safety conclusions regarding PML are fragile due to the rarity of events and the lack of adjusted analyses for JC virus status in most studies. The pooled estimate for PML risk is imprecise, and the possibility of residual confounding cannot be excluded.

4.3. Limitations of the Review Procedure

Our review followed PRISMA 2020 guidelines (15). However, several limitations should be acknowledged. The search was restricted to studies published after 2015 and in English, which may have induced bias. Due to heterogeneity in outcome definitions, narrative synthesis was required for the majority of efficacy outcomes. Finally, the small number of papers for each outcome limited our formal assessment of publication bias. The inclusion of one study from late 2014 (published in 2015) is a minor change from the protocol, stated for transparency.

4.4 Implications for Practice and Research

Clinical implications: For patients with stable RRMS, EID (≤8 weeks) may provide a reasonable balance of efficacy and convenience. However, the choice to lengthen dose intervals should be made on an individual basis. PML risk should not be the primary reason for switching to EID, as the evidence is still equivocal. Our findings highlight the importance of starting alternative therapy as soon as possible for patients who have stopped using natalizumab.

Future research should focus established criteria for EID and outcomes, large prospective registries with adjusted confounders, RCTs powered by clinical outcomes, and comparative efficacy research on post-cessation interventions.

5. Conclusion.

This systematic review compiles data from 28 research on natalizumab dose and discontinuation in relapsing-remitting multiple sclerosis. It suggests that extended-interval dosing (EID; up to 8 weeks) is as effective as

standard-interval dosing (SID) for relapse prevention (low certainty evidence). No statistically significant change in PML risk was observed, although the evidence is uncertain due to imprecision from rare events and possibly residual confounding. The discontinuation of natalizumab is associated with a significant absolute risk of disease reactivation, with a pooled 37.6% of patients relapsing within 12 months (low certainty evidence).

In clinical practice, these findings support EID as a viable choice for chosen, stable patients, mostly for convenience, while cautioning against using EID merely to reduce PML risk based on available evidence. The high relapse risk following cessation emphasizes the vital requirement for early beginning of alternative therapy. Future research should focus on prospective studies with consistent definitions and bigger sample numbers. In conclusion, while EID appears to be a suitable effective approach, treatment decisions must be highly personalized and informed by ongoing risk-benefit analysis.

6. Statements and Declarations

6.1 Competing Interests
The authors declare that they have no competing interests.

6.2 Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

6.3 Ethics Approval and Consent to Participate
Not applicable. This study is a systematic review and meta-analysis of previously published data.

6.4 Consent for Publication
Not applicable.

6.5 Availability of Data and Materials
All data analyzed in this study were obtained from previously published sources. No new datasets were generated or analyzed during the current study.

6.6 Author Contributions
All authors contributed to the conception, study design, data extraction, analysis, interpretation, and drafting of the manuscript. All authors read and approved the final version of the manuscript.

7. References

1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816–21.

2. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899–910.

3. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 Jan 2;348(1):15–23.

4. Ohlmeier C, Gothe H, Haas J, Osowski U, Weinhold C, Blauwitz S, et al. Epidemiology, characteristics and treatment of patients with relapsing-remitting multiple sclerosis and incidence of high disease activity: real-world evidence based on German claims data. PLoS One. 2020;15(5):e0231846.

5. Bomprezzi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord. 2014 Sep;7(5):227–31.

6. Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis. 2008;5(1):16–22.

7. McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs. 2013 Sep;73(13):1463–81.

8. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology. 1999 Aug 10;53(3):466–72.

9. Sheridan C. Tysabri back on market. Nat Biotechnol. 2006 Aug;24(8):874.

10. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 2;354(9):924–33.

11. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):911–23.

12. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch Med Sci. 2010 Apr 30;6(2):236–44.

13. Salhofer-Polanyi S, Baumgartner A, Kraus J, Maida E, Schmied M, Leutmezer F. What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand. 2014 Aug;130(2):97–102.

14. Rabea EM, Belal MM, Hafez AH, Elbanna AH, Khalifa MA, Nourelden AZ, et al. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Acta Neurol Belg. 2024 Apr;124(2):407–17.

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.

16. Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, et al. Significant clinical worsening after natalizumab withdrawal: predictive factors. Mult Scler. 2015 May;21(6):780–5.

17. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016 Dec 5;5(1):210.

18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.

19. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898.

20. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919.

21. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020 Oct;18(10):2127–33.

22. McGuinness LA, Higgins JPT. Risk-of-bias Visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021 Jan;12(1):55–61.

23. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020 Jan 16;368:l6890.

24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924–6.

25. R Core Team. R: The R Project for Statistical Computing [Internet]. Vienna: R Foundation for Statistical Computing; 2025 [cited 2025 Sept 26]. Available from: https://www.r-project.org/

26. Schwarzer G. meta: General Package for Meta-Analysis [Internet]. CRAN; 2025 [cited 2025 Sept 26]. Available from: https://cran.r-project.org/web/packages/meta/index.html

27. Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019 Oct 8;93(15):e1452–62.

28. Al-Mahdawi A, Hatem A, Hossam HM, et al. Efficacy and safety of natalizumab's extended interval dosing in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2023; [cited 2025 Sept 12]. Available from: https://www.sciencedirect.com/science/article/pii/S2211034823007022

29. Bernardes C, Fernandes C, Cunha C, Nunes C, Macário C, Sousa L, et al. Natalizumab extended interval dosing: what about wearing-off effect? J Neurol Sci. 2024 Mar 15;458:120–6.

30. Butzkueven H, Kappos L, et al. Similar clinical outcomes for natalizumab patients switching to every-6-week dosing versus remaining on every-4-week dosing in real-world practice. Presented at: ACTRIMS-ECTRIMS; 2020. Available from: https://a2-downloads.de/…

31. Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, et al. Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics. 2019;16(2):448–56.

32. Coerver EME, Wessels MHJ, van Lierop ZYG, van Kempen ZLE, Killestein J, Strijbis EMM. Natalizumab discontinuation in a Dutch real-world cohort. Mult Scler Relat Disord. 2021 Jul;52:102974.

33. De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, et al. MRI activity and extended interval natalizumab dosing regimen: a multicentre Italian study. J Neurol Sci. 2021 May 15;424:117385.

34. Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, et al. Switching to 6-week dosing of natalizumab versus continuing 4-week dosing in RRMS (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):608–19.

35. Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, Valero-López G, Iniesta-Martínez F, Cabrera-Maqueda JM, et al. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis: study of two high-dose methylprednisolone schedules. Mult Scler Relat Disord. 2020 Sep 1;44:102274.

36. Gardinetti M, Barcella V, Frigeni B, Frigo M, Fusco ML, Rottoli M. Natalizumab withdrawal in multiple sclerosis RR patients: what to expect. Neurol Disord Ther. 2017;1(1):1–8.

37. González-Suarez I, Rodríguez de Antonio L, Orviz A, Moreno-García S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after natalizumab discontinuation. Brain Behav. 2017 Apr;7(4):e00671.

38. Haas J, Schneider K, Schwarz A, Korporal-Kuhnke M, Faller S, von Glehn F, et al. Th17 cells: a prognostic marker for MS rebound after natalizumab cessation? Mult Scler. 2016 Jan;23(1):114–8.

39. Jakimovski D, Kavak KS, Zakalik K, McGraw C, Gottesman M, Coyle PK, et al. Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State MS Consortium study. J Neurol Sci. 2023 Dec 15;455:122781.

40. Jeantin L, Boudot de la Motte M, Deschamps R, Gueguen A, Gout O, Lecler A, et al. Natalizumab extended-interval dosing in a real-life setting. J Neurol Sci. 2023 Jul 15;450:120689.

41. Kaufman M, Cree BAC, de Sèze J. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015 Feb;262(2):426–36.

42. Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, et al. Predictors of relapse and disability progression after discontinuing DMTs in MS. J Neurol Sci. 2018 Aug;391:72–6.

43. Mustonen T, Rauma I, Hartikainen P, Krüger J, Niiranen M, Selander T, et al. Risk factors for reactivation of clinical disease activity in MS after natalizumab cessation. Mult Scler Relat Disord. 2020 Feb;38:101493.

44. Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, et al. Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm. 2016 Nov;3(6):e297.

45. Pelle J, Briant AR, Branger P, Derache N, Arnaud C, Lebrun-Frenay C, et al. Real-world effectiveness of natalizumab extended-interval dosing in a French cohort. Neurol Ther. 2023;12(2):529–42.

46. Riancho J, Setien S, Sánchez de la Torre JR, Torres-Barquin M, Misiego M, Pérez JL, et al. Does extended-interval dosing of natalizumab preserve effectiveness in multiple sclerosis? A 7-year retrospective observational study. Front Immunol. 2021 Mar 25;12:614715.

47. Ruggieri S, Ianniello A, Grimaldi LM, et al. Different regimen of natalizumab treatment in multiple sclerosis patients: a real-world study in Italy. Mult Scler Relat Disord. 2019;28:213–20.

48. Ryerson LZ. Extending natalizumab treatment up to eight weeks: updated multicenter analysis. 2015. Available from: https://www.researchgate.net/publication/282766495

49. Toljan K. Extended interval dosing of natalizumab: more evidence in support. Neurotherapeutics. 2024;21(1):38–43.

50. Toorop AA, Noteboom S, Steenwijk MD, Gravendeel JW, Jasperse B, Barkhof F, et al. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in MS. Mult Scler. 2024 Feb;30(2):266–71.

51. van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI, et al. Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial. Neurology. 2020 Aug 11;95(6):e745–54.

52. Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, et al. Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):937–43.

53. Yamout B. Efficacy and safety of natalizumab extended-interval dosing. Mult Scler Relat Disord. 2018 Jan;24:113–6.

Risk of bias domains

Study	D1	D2	D3	D4	D5	Overall
Kaufman (RESTORE), 2015	+	-	+	+	+	+
Foley et al., 2022 (NOVA)	+	+	+	+	+	+
Wein stock Guttman et al., 2016	-	X	+	-	+	-

Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

Judgement
- X High
- - Some concerns
- + Low

Risk of bias domains

Study	D1	D2	D3	D4	D5	D6	D7	Overall
Ryerson, 2015	−	+	+	+	+	−	+	−
Ruggieri, 2019	−	+	+	+	−	+	+	−
Butzkueven, 2020	−	−	+	+	+	+	+	−
Toorop, 2024	X	+	+	−	+	+	+	X
Al-Mahdawi, 2023	−	+	+	+	+	+	+	−
Coerver, 2021	−	+	+	+	+	+	+	−
Clerico, 2019	−	+	+	+	−	+	+	−
Gardinetti, 2021	X	−	+	+	+	−	−	X
Jeantin, 2023	−	+	+	+	−	−	+	−
Riancho, 2021	X	−	+	X	−	+	−	X
Yamout, 2018	X	−	+	+	−	+	+	−
Toljan, 2024	−	X	+	−	−	+	+	−
Bernardes et al., 2024	−	+	+	+	+	−	+	−
De Mercanti et al., 2021	−	+	+	+	+	X	+	−
Fuentes Rumí et al., 2020	−	+	+	+	+	−	+	−
Haas et al., 2016	−	−	+	+	+	+	+	−
Jakimovski et al., 2023	−	+	+	+	+	+	+	−
Kister et al., 2018	−	−	+	+	+	+	+	−
Mustonen et al., 2020	−	+	+	+	+	+	+	−
Papeix et al., 2016	−	−	+	+	X	+	+	−
Pelle et al., 2023	−	+	+	−	X	+	+	X
van Kem pen et al., 2020	−	+	+	+	+	+	+	−
Vidal Jordana et al., 2015	−	+	+	−	+	+	+	−
Ryerson et al 2019	−	−	+	+	+	+	+	−

Domains:
D1: Bias due to confounding.
D2: Bias due to selection of participants.
D3: Bias in classification of interventions.
D4: Bias due to deviations from intended interventions.
D5: Bias due to missing data.
D6: Bias in measurement of outcomes.
D7: Bias in selection of the reported result.

Judgement
X Serious
− Moderate
+ Low

Study	Experimental		Control		Risk Ratio	RR	95%–CI	Weight
	Events	Total	Events	Total				
Butzkueven et al., 2020	2	236	2	210		0.89	[0.13; 6.26]	51.5%
Ryerson et al., 2019	1	810	19	4801		0.31	[0.04; 2.33]	48.5%
Clerico et al., 2019	0	144	0	216				0.0%
Pelle et al., 2023	0	147	0	156				0.0%
Riancho et al., 2021	0	39	0	39				0.0%
Toorop et al., 2024	0	32	0	50				0.0%
Yamout et al., 2018	0	85	0	85				0.0%
Random effects model		**1493**		**5557**		**0.54**	**[0.13; 2.17]**	**100.0%**
Heterogeneity: $I^2 = 0.0\%$, $\tau^2 = 0$, $p = 0.4633$								

Risk Ratio (excluding Foley 2022)